ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.83 -0.60%

-$0.13 today

Market cap
$3.08B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.89M

Average 1.66M

ACAD Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

ACADIA Pharmaceuticals Inc.NASDAQ: ACAD

Net Margin · Q3 FY2026 · quarter ended Sep 2026

Net margin narrows to 15.6%

Net margin was 15.6% in Q3 FY2026, down 10.1 pp from a year earlier. On a trailing-twelve-month basis it was 30.1%, up 5.2 pp year over year. Over 3 fiscal years it widened by 78.2 pp.

Context

  • Net margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 14 analysts of 10.2% for the fiscal year ending Dec 2026, down from 36.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
15.6%+5.4 pp QoQ
Last fiscal yearDec 2025
36.5%+12.8 pp YoY
LTMSep 2026
30.1%+5.2 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-10.1 pp-83.5 pp-73.3 pp
1 year+12.8 pp-26.3 pp-39.1 pp
3 years+78.2 pp-16.9 pp-95.1 pp
5 years-13.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
36.5%
Year-over-year change
+12.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ACAD compares with its peers on the latest reported figures

  • ACAD's LTM Sep 2026 net margin of 30.1% is the highest of the 4 companies compared; the peer median is -110.0%.
  • Its year-over-year change of +5.2 pp is the 2nd highest of 3, against a peer median of -31.4 pp.
  • Over three fiscal years its change of +78.2 pp compares with a peer median of +120.4 pp.
ACAD Competitors Peer median
Net Margin for ACAD and competitors
Company Period LTM level YoY 3-year change
ACADACADIA Pharmaceuticals Inc.LTM Sep 202630.1% +5.2 pp+78.2 pp
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-24.7% +25.2 pp+345.3 pp
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-110.0% -88.0 pp-104.5 pp
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-536.4% ——
PRAXPraxis Precision Medicines, Inc.FY2025— ——
LBRXLB Pharmaceuticals Inc Common StockFY2025— ——
ANROAlto Neuroscience, Inc.FY2025— ——
CTNMContineum Therapeutics, Inc. Class A Common StockFY2025— ——
MPLTMapLight Therapeutics, Inc.FY2025— ——
AVXLAnavex Life Sciences Corp.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding ACAD) -110.0%-31.4 pp+120.4 pp

Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue484.15M517.24M726.44M957.8M1.07B
Cost of Revenue19.14M10.17M45.73M81.84M89M
Gross Profit465M507.07M680.71M875.96M982.51M
Gross Margin96.0%98.0%93.7%91.5%91.7%
Research & Development239.42M361.58M351.62M303.25M328.8M
Selling, General & Admin396.03M369.09M402.47M488.43M548.89M
Operating Expenses635.44M730.67M754.09M645.16M877.7M
Depreciation & Amortization3.34M2.03M5.55M15.88M11.76M
EBITDA(164.18M)(211.42M)(45.48M)100.16M150.66M
EBITDA Margin-33.9%-40.9%-6.3%10.5%14.1%
Operating Income(170.44M)(223.6M)(73.38M)230.79M104.81M
Operating Margin-35.2%-43.2%-10.1%24.1%9.8%
Interest Income591K6.61M17.23M25.46M31.72M
Interest Expense00000
Other Income / Expenses2.92M10.15M22.34M27.28M34.09M
Income Before Tax(167.52M)(213.44M)(51.04M)258.08M138.9M
Pre-Tax Margin-34.6%-41.3%-7.0%26.9%13.0%
Income Tax Expense351K2.53M10.25M31.62M(252.1M)
Net Income(167.87M)(215.98M)(61.29M)226.45M391M
Net Margin-34.7%-41.8%-8.4%23.6%36.5%
EPS (Basic)(1.05)(1.34)(0.37)1.372.32
EPS (Diluted)(1.05)(1.34)(0.37)1.362.29
Weighted Avg Shares160.49M161.68M163.82M165.72M169.34M
Weighted Avg Shares (Diluted)160.49M161.68M163.82M166.36M171.36M

ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Intrinsic Alpha fair value

Locked

Current Price

$17.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.